No Love: Chinese Oncology Firms Scramble To Cope With New US Reality

 
• By Brian Yang

After a high-profile FDA advisory committee rejection of potentially the first "Made In China" cancer drug in the US, from Innovent Bio and partner Lilly, many Chinese oncology companies are now quietly looking for the next step forward.

No Love for Made in China PD-1s from US FDA
CHINESE CANCER DEVELOPERS SCRAMBLE TO COPE AFTER FDA COMMITTEE REQUIRES ADDITIONAL DATA • Source: Alamy

More from US FDA Performance Tracker

More from Regulatory Trackers